Meeting the need for regenerative therapies I: Target-based incidence and its relationship to U.S spending, productivity, and innovation

Tissue Engineering - Part B: Reviews

Volumn 18, Issue 2, 2012, Pages 139-154

  Parenteau, Nancy ^a   Hardin Young, Janet ^a   Shannon, William ^b,c   Cantini, Patrick ^d   Russell, Alan ^d,e  

^a Parenteau BioConsultants   (United States)

^b BioRankings   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

^e PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC RESEARCH; CLINICAL PRACTICES; EFFECTIVE TRANSLATION; INTERDISCIPLINARITY; MEDICAL ADVANCES; MEDICAL NEEDS; RESEARCH SPENDING; SIMULTANEOUS INTEGRATION; START-UPS; STRATEGIC DECISION MAKING;

RESEARCH;

PRODUCTIVITY;

ARTICLE; CARDIAC PATIENT; CLINICAL PRACTICE; DECISION MAKING; FUNDING; GENETIC DISORDER; HEALTH CARE NEED; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; INVESTMENT; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NATIONAL HEALTH ORGANIZATION; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PRODUCTIVITY; REGENERATIVE MEDICINE; SCIENTIST; STEM CELL RESEARCH; STROKE; TISSUE ENGINEERING; TISSUE REGENERATION; UNITED STATES;

BIOMEDICAL RESEARCH; DISEASE; EFFICIENCY; HUMANS; INVESTMENTS; NATIONAL INSTITUTES OF HEALTH (U.S.); ORGANIZATIONAL INNOVATION; REGENERATIVE MEDICINE; STEM CELL RESEARCH; TECHNOLOGY TRANSFER; TISSUE ENGINEERING; UNITED STATES;

EID: 84858975191     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2011.0454     Document Type: Article

References (43)

1. Luce, C.B, and Giovannetti, G. The Ernst & Young Business Risk Report-Life Sciences. New York: EYGM Ltd., 2009 p. 10.
2. Frantz, S. Pipeline problems are increasing the urge to merge. Nat Rev Drug Discov 5, 977, 2006.
3. Mintz, C. The potential of personalized medicine: Life Science Leader. Sewickley, PA: VertMarkets, 2010.
4. Conway, B. Big pharma reassesses orphan drug sector. Wall Street BioBeat, 30, 5, 2010.
5. Services DoHaH. Regenerative Medicine. Bethesda, MD: US Department of Health and Human Services, 2006. /info/scireport/2006report.htm . Accessed September 25, 2010.
6. Cooksey, D. The Review and Refresh of Bioscience 2015. A Report to Government by the Bioscience Innovation and Growth Team London: Office for Life Sciences, 2009. www .berr.gov.uk/files/file49805.pdf. Accessed September 3, 2010.
7. Gallico, G.G., 3rd, O'Connor, N.E., Compton, C.C., Kehinde, O., and Green, H. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 311, 448, 1984.
8. Parenteau, N. Skin: the first tissue-engineered products. Sci Am 280, 83, 1999.
9. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145, 1998.
10. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143, 1999.
11. Takahashi,K., Tanabe,K., Ohnuki,M.,Narita, M., Ichisaka, T., Tomoda, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861, 2007.
12. Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4, 381, 2009.
13. Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618, 2010.
14. Johnson, P.C., Bertram, T.A., Tawil. B., and Hellman, K.B. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry. Tissue Eng Part A 17, 5, 2011.
15. DeFrances, C.J., Lucas, C.A., Buie, V.C., and Golosinskiy, A. 2006 National Hospital Discharge Survey. Natl Health Stat Rep 1, 2008.
16. Dennison, C.F., and Pokras, R. Design and operation of the national hospital discharage survey: 1988 Redesign. In: Statistics NCfH, ed. Hyattsville, M.D: Center for Disease Control and Prevention, 2000.
17. Health NIo. Research Portfolio Online Reporting Tools (RePORT). Bethesda, MD: National Institutes of Health 2010. http://report.nih.gov/. Accessed May 19, 2011.
18. Kinnaird, T., Stabile, E., Burnett, M.S., Shou, M., Lee, C.W., Barr, S., et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109, 1543, 2004.
19. Rosenstrauch, D., Poglajen, G., Zidar, N., and Gregoric, I.D. Stem celltherapy for ischemic heart failure. Tex Heart Inst J 32, 339, 2005.
20. Menasche, P., Alfieri, O., Janssens, S., McKenna, W., Reichenspurner, H., Trinquart, L., et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117, 1189, 2008.
21. Hunt, S.A., Baker, D.W., Chin, M.H., Cinquegrani, M.P., Feldman, A.M., Francis, G.S., et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104, 2996, 2001.
22. DOPPS. Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1999-2008. Annual Report of the Dialysis Outcomes and Practice Patterns Study. Ann Arbor: Ann Arbor Research Collaborative for Health; 2009.
23. Hickey, E., Langley, S.M., Allemby-Smith, O., Livesey, S.A., and Monro, J.L. Subcoronary allograft aortic valve replacement: parametric risk-hazard outcome analysis to a minimum of 20 years. Ann Thorac Surg 84, 1564, 2007.
24. Lupinetti, F.M., Duncan, B.W., Scifres, A.M., Fearneyhough, C.T., Kilian, K., Rosenthal, G.L., et al. Intermediate-term results in pediatric aortic valve replacement. Ann Thorac Surg 68, 521, 1999.
25. Hootman, J.M., and Helmick, C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 54, 226, 2006.
26. Lindvall, O., and Kokaia, Z. Stem cells in human neurodegenerative disorders-time for clinical translation? J Clin Invest 120, 29, 2010.
27. Mehta, T., Feroz, A., Thakkar, U., Vanikar, A., Shah, V., and Trivedi, H. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc 40, 1145, 2008.
28. Parenteau, N.L. Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum. Regen Med 4, 601, 2009.
29. Brundin, P., Barker, R.A., and Parmar, M. Neural grafting in Parkinson's disease problems and possibilities. Prog Brain Res 184, 265, 2010.
30. Lane, E.L., Bjorklund,A., Dunnett, S.B., andWinkler, C. Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft- induceddyskinesia. Prog BrainRes 184, 295, 2010.
31. Politis, M., Wu, K., Loane, C., Quinn, N.P., Brooks, D.J., Rehncrona, S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2, 38ra46, 2010.
32. Menasche, P. Stem Cell Therapy for Heart Failure: Are Arrrhymias a Real Safety Concern? Circulation 119, 2735, 2009.
33. Uccelli, A., and Mancardi, G. Stem cell transplantation in multiple sclerosis. Curr Opin Neurol 23, 218, 2010.
34. Mitchell, C., Mignon, A., Guidotti, J.E., Besnard, S., Fabre, M., Duverger, N., et al. Therapeutic liver repopulation in a mouse model of hypercholesterolemia. HumMol Genet 9, 1597, 2000.
35. Piscaglia, A.C., Campanale, M., Gasbarrini, A., and Gasbarrini, G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int 2010, 259461, 2010.
36. Parenteau, N.L., Rosenberg, L., and Hardin-Young, J. The engineering of tissues using progenitor cells. Curr Top Dev Biol 64, 101, 2004.
37. Quante,M., andWang, T.C. Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 6, 724, 2009.
38. Robertson, R.P. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 59, 1285, 2010.
39. Jun, H.S. Cell replacement and regeneration therapy for diabetes. Korean Diabetes J 34, 77, 2010.
40. Mandel, M. The failed promise of innovation in the US: Business Week. New York: Bloomberg, 2010.
41. Caplan, A.I. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 11, 1198, 2005.
42. US FDA Orphan Drug Act. USA Public Law 97-414, www.fda.gov/ RegulatoryInformation/Legislation/Federal FoodDrugandCosmeticActFDCAct/ SignificantAmendments totheFDCAct/OrphanDrugAct/default.htm. Accessed June 27, 2011.
43. National Science Board, Science and Engineering Indicators 2010.National Science Foundation, 2010. www.nsf.gov/statistics/seind10/. Accessed July.26.2010.